Searchable abstracts of presentations at key conferences in endocrinology

ea0081p546 | Calcium and Bone | ECE2022

Trabecular bone score captures low bone quality in women with normal bone mineral density or osteopenia initiating aromatase inhibitors for breast cancer

Zavatta Matteo Malagrino, Paola Altieri, Uberto Pagotto & Guido

Introduction: Hypoparathyroidism Bone Score (TBS) has been associated with fragility fractures in post-menopausal women. Estrogen-receptor positive breast cancer is usually treated with aromatase inhibitors (AIs), with international guidelines recommending initial bone density (BMD) evaluation, since this therapy is associated with high rates of fragility fractures. Each Country has different thresholds of intervention to recommend pharmacologic treatment for fracture preventi...

ea0081p561 | Calcium and Bone | ECE2022

Nutritional and clinical manifestations of normocalcemic hyperparathyroidism in women: interim results from a case-control cross-sectional study evaluating dietary calcium intake with three validated questionnaires

Malagrino Matteo , Altieri Paola , Clarke Bart , Pagotto Uberto , Zavatta Guido

Context: Normocalcemic hyperparathyroidism (NHPT) is considered as an earlier or milder phenotype compared to traditional primary hyperparathyroidism (PHPT). To make a correct diagnosis, secondary hyperparathyroidism due to low calcium intake must be excluded. Whether calcium intake might affect presentation of PHPT vs NHPT has never been addressed consistently.Objective: To describe patients with a diagnosis of NHPT or PHPT in relation to their calcium ...

ea0081ep195 | Calcium and Bone | ECE2022

Management of denosumab discontinuation in a patient with osteonecrosis of the jaw and coexisting primary hyperparathyroidism

Malagrino Matteo , Belardinelli Elisabetta , Altieri Paola , Pagotto Uberto , Zavatta Guido

Context: Patients with primary hyperparathyroidism (PHPT) may be treated with denosumab due to coexisting osteoporosis. Few studies have been conducted in this population.Case presentation: An 84-year-old woman was seen in the outpatient clinic in March 2018 due to calcium levels at the upper limit of reference range (10,2 mg/dl) associated with elevated levels of PTH (112 pg/ml) and sufficient 25(OH)Vit D (24 ng/ml) levels, findings consistent with mild...

ea0073aep153 | Calcium and Bone | ECE2021

Unexpected association of severe hypercalcemia and hypophosphatemia in a patient with chronic hypoparathyroidism: A case report

Vandi Giulia , Zavatta Guido , Repaci Andrea , Altieri Paola , Pagotto Uberto

Clinical vignetteA 65-year-old woman was hospitalized due to severe hypercalcemia (albumin-corrected calcium 16.9 mg/dl) associated with severe renal failure (creatinine 3.48 mg/ml), normal phosphate levels (3.9 mg/dl) and PTH < 5 pg/ml. Her past medical history included total thyroidectomy complicated by chronic hypoparathyroidism, for which she was followed by her primary care physician. One year before hospital admission, renal function was normal...

ea0090p580 | Calcium and Bone | ECE2023

Low trabecular bone score better predicts prevalent vertebral fractures in younger rather than older women starting endocrine therapy for breast cancer

Malagrino Matteo , Piazza Anna , Bisceglia Nicolo , Vandi Giulia , Altieri Paola , Pagotto Uberto , Zavatta Guido

Context: Although Trabecular Bone Score (TBS) has been widely and independently associated with fragility fractures, its diagnostic power in certain populations remains to be established. Women initiating aromatase inhibitors for breast cancer should be screened for bone health to prevent cancer treatment-induced bone loss as much as possible. TBS is regarded as an adjunctive tool to evaluate these patients, but thresholds of pharmacologic interventions are still a gray zone, ...

ea0063p502 | Calcium and Bone 2 | ECE2019

Evaluation of bone metabolism in women on aromatase-inhibitors before and after antiresorptive treatment

Vandi Giulia , Zavatta Guido , Repaci Andrea , Di Dalmazi Guido , Altieri Paola , Pagotto Uberto

Introduction: Adjuvant therapy with aromatase-inhibitors (AIs) increases bone loss and fracture risk. Concomitant antiresorptive treatment is currently recommended. The aim of this study was to evaluate the effects of AIs on bone metabolism and mineral density at 12 and 24 months.Methods: Among 400 women on AIs who attended our Endocrinology Unit from 2014 to 2016, we retrospectively evaluated those who initially refused antiresorptive and took cholecalc...

ea0063p515 | Calcium and Bone 2 | ECE2019

Denosumab, alendronate and zoledronate failure to suppress bone resorption markers in a woman affected by severe osteoporosis and subclinical hypercortisolism due to an adrenal adenoma: A case report

Zavatta Guido , Preiato Valentina Lo , Vandi Giulia , Vicennati Valentina , Di Dalmazi Guido , Pagotto Uberto , Altieri Paola

Context: ß-CTX are considered useful markers of response to denosumab and other anti-resorbtive treatments for osteoporosis. We report an unusual case of a completely absent effect of both denosumab and bisphosphonates on bone resorption markers.Case description: In 2017 a 74-year-old woman sought medical attention at the Endocrinology Unit of Policlinico di SantÂ’Orsola for the evaluation of an adrenal adenoma associated with osteoporosis. Meno...

ea0063p521 | Calcium and Bone 2 | ECE2019

A rare case of cushing disease and hypophosphatasia

Preiato Valentina Lo , Zavatta Guido , Ribichini Danilo , Altieri Paola , Pelusi Carla , Pagotto Uberto

Cushing disease and hypophosphatasia are rare conditions that may be both responsible of an important impairment of bone metabolism with increased fracture risk. We reported for the first time a case of a 43-year-old woman that came at our attention for recent onset of alopecia and amenorrhea. At the anamnesis, she denied any past relevant events and no drug assumption. At the physical examination, she presented rubeosis and facies lunaris and central adipose distribution (wai...

ea0056p224 | Calcium &amp; Vitamin D metabolism | ECE2018

Clinical manifestation of Hypoparathyroidism in a monocentric cohort: our experience

Repaci Andrea , Altieri Paola , Dianori Francesco , Salituro Nicola , Vandi Giulia , Pagotto Uberto

Introduction: Hypoparathyroidism (HP) is characterized by low serum calcium and increased phosphate levels associated with inappropriately low serum PTH levels. Clinical manifestations of HP are tingling, muscle cramps, seizures, nephrocalcinosis, kidney stone, kidney failure, depression and anxiety.Objective: Quantify the chronic symptoms and complications of HP in our monocentric cohort.Material and methods: We conducted a retros...

ea0099oc10.1 | Oral Communications 10: Calcium and Bone | Part II | ECE2024

Time to severe chronic kidney disease and nephrolithiasis in hypoparathyroidism: results from a large longitudinal retrospective study

Piazza Anna , Bisceglia Nicolo , Malagrino Matteo , Altieri Paola , Repaci Andrea , Pagotto Uberto , Zavatta Guido

Introduction: Hypoparathyroidism (Hypo) is associated with a higher risk of chronic kidney disease (CKD) and renal stones, although the time to onset of these complications in the diseaseÂ’s natural history has never been explored. Calcium-Phosphate product (CaxP) has been shown to be a risk factor for moderate renal disease in Hypo in a limited number of cross-sectional or case-control studies.Objective: To determine the time of onset of incident se...